What rare lysosomal storage disease is the target of a new drug, Avlayah, granted accelerated FDA approval in March 2026?

The rare lysosomal storage disease targeted by the newly approved drug Avlayah is Hunter syndrome. This inherited condition, also known as mucopolysaccharidosis type II (MPS II), primarily affects males and is characterized by the body's inability to produce sufficient amounts of a crucial enzyme called iduronate 2-sulfatase (IDS). Without this enzyme, complex sugar molecules known as glycosaminoglycans (GAGs) accumulate within the lysosomes of cells throughout the body. This buildup leads to progressive damage in various organs and tissues, impacting physical development and, significantly, neurological function.

Historically, a major challenge in treating Hunter syndrome, particularly its neurological manifestations, has been the difficulty of getting therapeutic enzymes to cross the blood-brain barrier. Previous enzyme replacement therapies could not effectively reach the brain, leaving the cognitive and behavioral aspects of the disease largely untreatable. Avlayah (tividenofusp alfa-eknm) represents a significant advancement because it is specifically engineered to overcome this barrier.

Granted accelerated FDA approval in March 2026, Avlayah is the first therapy designed to deliver the IDS enzyme directly to both the body and the brain. The approval was based on its ability to significantly reduce heparan sulfate, a key disease biomarker, in the cerebrospinal fluid. This breakthrough offers new hope for children with Hunter syndrome, as it is the first new treatment option in nearly two decades specifically aimed at addressing the debilitating neurological symptoms of this rare and progressive disorder.